Metabolic
Tesamorelin
GHRH Analogue
Also referred to as TH9507.
Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone with a trans-3-hexenoyl modification that resists enzymatic degradation. It is among the comparatively small set of research peptides with completed phase III human trials.
Published on Tesamorelin
- Research OverviewTesamorelin Peptide: Is It Safe? Side Effects and Risks in the ResearchTesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), constructed as a trans-3-hexenoic acid conjugate of the full 44-amino acid GHRH sequence.
- Research OverviewTesamorelin Peptide Combinations: What the Research Says About StackingTesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) — specifically, a stabilized form of the endogenous 44-amino-acid peptide — developed to stimulate pulsatile release of growth hormone from the pituitary gland.
- Research OverviewTesamorelin Peptide: Research Outcomes and What Studies ReportTesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) — a 44-amino-acid peptide that stimulates the pituitary gland to produce and release endogenous growth hormone (GH).
- Research OverviewTesamorelin Peptide: Mechanism of Action ExplainedTesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), a 44-amino acid hypothalamic peptide that stimulates the anterior pituitary to secrete growth hormone (GH).